BCCA Protocol Summary for Second-line Treatment of Recurrent Small Cell Lung Cancer (SCLC) with Topotecan

Protocol Code                  LUSCTOP
Tumour Group                   Lung
Contact Physician              Dr. Christopher Lee

ELIGIBILITY:
- Recurrent/progressive small cell lung cancer following first-line therapy
- ECOG performance status 0-2
- Relative contraindication to LUSCCAV

EXCLUSIONS:
- ECOG performance status 3-4

TESTS:
- Baseline: CBC & diff (including platelets), electrolytes, BUN, creatinine
- Before each treatment: CBC & diff (including platelets), creatinine
- Weekly: CBC & diff (including platelets)

PREMEDICATIONS:
- Antiemetic protocol for Low-Moderate emetogenic chemotherapy (see protocol SCNAUSEA)

TREATMENT:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>topotecan</td>
<td>1.5 mg/m²/day x 5 days (days 1-5)</td>
<td>IV in 50mL NS over 30 minutes</td>
</tr>
</tbody>
</table>

- Repeat 5-day treatment every 21 days x 4-6 cycles

DOSE MODIFICATIONS:
1. Hematology:
   a) on treatment day:

<table>
<thead>
<tr>
<th>ANC (x 10⁹/L)</th>
<th>Platelets (x 10⁹/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 1.0 and greater than or equal to 100</td>
<td>treat as per nadir</td>
<td></td>
</tr>
<tr>
<td>less than 1.0 or less than 100</td>
<td>delay until recovery</td>
<td></td>
</tr>
</tbody>
</table>

   b) at nadir:

<table>
<thead>
<tr>
<th>ANC (x 10⁹/L)</th>
<th>Platelets (x 10⁹/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>less than 0.5 or less than 50</td>
<td>decrease by 0.25 mg/m²/day*</td>
<td></td>
</tr>
</tbody>
</table>
2. **Any Grade 3 or 4 toxicity (except nausea):** decrease dose by 0.25mg/m²/day*

*e.g. if initial dose is 1.5 mg/m²/day x 5 days → 1.25 mg/m²/day x 5 days.
    if initial dose is 1.25 mg/m²/day x 5 days → 1.0 mg/m²/day x 5 days.

3. **Renal Dysfunction:**

<table>
<thead>
<tr>
<th>Creatinine Clearance (mL/min)</th>
<th>Topotecan Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 40</td>
<td>100%</td>
</tr>
<tr>
<td>20-39</td>
<td>50%</td>
</tr>
<tr>
<td>less than 20</td>
<td>not recommended</td>
</tr>
</tbody>
</table>

\[
\text{CrCl (mL/min)} = \frac{N \times (140 - \text{age}) \times \text{weight (kg)}}{\text{serum creatinine (µmol/L)}}
\]

where N = 1.04 for females and 1.23 for males

**PRECAUTIONS:**
1. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.

**Call Dr. Christopher Lee or tumour group delegate at (604) 930-2098 or 1-800-523-2885 with any problems or questions regarding this treatment program.**

Date activated: 01 December 2004
Date revised: 01 Sep 2015 (Class II requirement deleted)

**REFERENCES:**